High mobility group box 1 and kidney diseases (Review)

International Journal of Molecular Medicine

Volumn 31, Issue 4, 2013, Pages 763-768

  Zhu, Ping ^a   Xie, Li ^a   Ding, Hua Sheng ^a   Gong, Quan ^b   Yang, Jian ^a   Yang, Lin ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

High mobility group box 1; Kidney diseases; Receptor for advanced glycation end products; Toll like receptors

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CRYOPYRIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DNA; GAMMA INTERFERON; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC42; PROTEIN P16; PROTEIN P53; RAG1 PROTEIN; RAG2 PROTEIN; STEROID RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ALPHA HELIX; ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ANTIGEN PRESENTING CELL; ARTICLE; CELL CYCLE CHECKPOINT; CELL CYCLE S PHASE; DIABETIC NEPHROPATHY; DNA BINDING; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FLUORESCENCE RESONANCE ENERGY TRANSFER; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSCRIPTION; GLOMERULONEPHRITIS; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; RECEPTOR BINDING; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; HMGB1 PROTEIN; HUMANS; KIDNEY DISEASES; MICE; RATS;

EID: 84875263230     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1286     Document Type: Article

References (61)

1. Goodwin GH, Sanders C and Johns EW: A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 38: 14-19, 1973.
2. Bustin M, Lehn D and Landsman D: Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1049: 231-243, 1990.
3. Bonaldi T, Längst G, Strohner R, Becker PB and Bianchi ME: The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J 21: 6865-6873, 2002.
4. Travers AA: Priming the nucleosome: a role for HMGB proteins? EMBO Rep 4: 131-136, 2003.
5. Hock R, Furusawa T, Ueda T and Bustin M: HMG chromosomal proteins in development and disease. Trends Cell Biol 17: 72-79, 2007.
6. Ferrari S, Finelli P, Rocchi M and Bianchi M: The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics 35: 367-371, 1996.
7. Kornblit B, Munthe-Fog L, Petersen S, Madsen H, Vindeløv L and Garred P: The genetic variation of the human HMGB1 gene. Tissue Antigens 70: 151-156, 2007.
8. Landsman D and Bustin M: A signature for the HMG-1 box DNA-binding proteins. Bioessays 15: 539-546, 1993.
9. Han J, Zhong J, Wei W, et al: Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 57: 2118-2127, 2008.
10. Dintilhac A and Bernués J: HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J Biol Chem 277: 7021-7028, 2002.
11. Weir H, Kraulis P, Hill C, Raine A, Laue E and Thomas J: Structure of the HMG box motif in the B-domain of HMG1. EMBO J 12: 1311-1319, 1993.
12. Messmer D, Yang H, Telusma G, et al: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173: 307-313, 2004.
13. Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101: 296-301, 2004.
14. Calogero S, Grassi F, Aguzzi A, et al: The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 22: 276-280, 1999.
15. Müller S, Scaffidi P, Degryse B, et al: New EMBO member's review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 20: 4337-4340, 2001.
16. Ulloa L, Batliwalla FM, Andersson U, Gregersen PK and Tracey KJ: High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum 48: 876-881, 2003.
17. Brickman JM, Adam M and Ptashne M: Interactions between an HMG-1 protein and members of the Rel family. Proc Natl Acad Sci USA 96: 10679-10683, 1999.
18. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
19. Bianchi ME and Manfredi AA: High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220: 35-46, 2007.
20. Lamkanfi M, Sarkar A, Vande Walle L, et al: Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 185: 4385-4392, 2010.
21. Park JS, Svetkauskaite D, He Q, et al: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377, 2004.
22. Kokkola R, Andersson A, Mullins G, et al: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61: 1-9, 2005.
23. Hori O, Brett J, Slattery T, et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 270: 25752-25761, 1995.
24. Yang H, Wang H, Czura CJ and Tracey KJ: The cytokine activity of HMGB1. J Leukoc Biol 78: 1-8, 2005.
25. Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J and Rauvala H: 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 266: 16722-16729, 1991.
26. Taguchi A, Blood DC, del Toro G, et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000.
27. Park JS, Gamboni-Robertson F, He Q, et al: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924, 2006.
28. Park JS, Arcaroli J, Yum HK, et al: Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284: C870-C879, 2003.
29. Yu M, Wang H, Ding A, et al: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26: 174-179, 2006.
30. Ivanov S, Dragoi AM, Wang X, et al: A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110: 1970-1981, 2007.
31. Tian J, Avalos AM, Mao SY, et al: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8: 487-496, 2007.
32. Oyama Y, Hashiguchi T, Taniguchi N, et al: High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest 90: 853-866, 2010.
33. Iwata Y, Furuichi K, Sakai N, et al: Dendritic cells contribute to autoimmune kidney injury in MRL-Faslpr mice. J Rheumatol 36: 306-314, 2009.
34. Zhou JG, Dong JY, Zhang LH and Wang J: Expression of high mobility group box chromosomal protein 1 in mice with lupus nephritis. Zhejiang Da Xue Xue Bao Yi Xue Ban 40: 200-206, 2011 (In Chinese).
35. Pisetsky DS: HMGB1: a smoking gun in lupus nephritis? Arthritis Res Ther 14: 112, 2012.
36. Feng X, Hao J, Liu Q, et al: HMGB1 mediates IFN-γ-induced cell proliferation in MMC cells through regulation of cyclin D1/CDK4/p16 pathway. J Cell Biochem 113: 2009-2019, 2012.
37. Zickert A, Palmblad K, Sundelin B, et al: Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 14: R36, 2012.
38. Bruchfeld A, Wendt M, Bratt J, et al: High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 17: 29-35, 2011.
39. Kim J, Sohn E, Kim CS, Jo K and Kim JS: The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol 33: 524-529, 2011.
40. Lin M, Yiu WH, Wu HJ, et al: Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 23: 86-102, 2012.
41. Penfold SA, Coughlan MT, Patel SK, et al: Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 78: 287-295, 2010.
42. Torres VE, Harris PC and Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007.
43. Nakamura T, Kawagoe Y, Ueda Y, Yamada S and Koide H: Hemoperfusion treatment in a septic shock patient with autosomal dominant polycystic kidney disease and increased HMGB1 protein levels. Blood Purif 32: 139-142, 2011.
44. Nakamura T, Sato E, Fujiwara N, et al: Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am J Med Sci 343: 46-51, 2012.
45. Hu YM, Pai MH, Yeh CL, Hou YC and Yeh SL: Glutamine administration ameliorates sepsis-induced kidney injury by downregulating the high-mobility group box protein-1-mediated pathway in mice. Am J Physiol Renal Physiol 302: F150-F158, 2012.
46. Wang Q, Yao YM, Wang YB, et al: Effect of ethyl pyruvate on renal high mobility group box-1 protein expression and acute kidney injury in rats with delayed resuscitation after thermal injury. Zhonghua Wai Ke Za Zhi 45: 1210-1213, 2007 (In Chinese).
47. Chen J, Hartono JR, John R, et al: Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int 80: 504-515, 2011.
48. Chung KY, Park JJ and Kim YS: The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc 40: 2136-2138, 2008.
49. Wu H, Ma J, Wang P, et al: HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 21: 1878-1890, 2010.
50. Li J, Gong Q, Zhong S, et al: Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol Dial Transplant 26: 469-478, 2011.
51. Bao YS, Na SP, Zhang P, et al: Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol 32: 587-594, 2012.
52. Bruchfeld A, Qureshi AR, Lindholm B, et al: High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 14: 109-115, 2008.
53. Sato F, Maruyama S, Hayashi H, et al: High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 108: c194-c201, 2008.
54. Leelahavanichkul A, Huang Y, Hu X, et al: Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing high mobility group box protein-1. Kidney Int 80: 1198-1211, 2011.
55. Nakamura T, Sato E, Fujiwara N, et al: Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 58: 1624-1628, 2009.
56. D'Agati V and Schmidt AM: RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 6: 352-360, 2010.
57. Lynch J, Nolan S, Slattery C, Feighery R, Ryan MP and McMorrow T: High-mobility group box protein 1: a novel mediator of inflammatory-induced renal epithelial-mesenchymal transition. Am J Nephrol 32: 590-602, 2010.
58. Sandim V, Pereira D, Ornellas A and Alves G: Renal cell carcinoma and proteomics. Urol Int 84: 373-377, 2010.
59. Lin L, Zhong K, Sun Z, Wu G and Ding G: Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 13: 11-22, 2012.
60. Ganji MR and Harririan A: Chronic allograft dysfunction: major contributing factors. Iran J Kidney Dis 6: 88-93, 2012.
61. Wang S, Schmaderer C, Kiss E, et al: Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling. Dis Model Mech 3: 92-103, 2010.